Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 41-50 of 297 for Lung cancer

Edit search filters
  1. A Study of ASP8273 versus Erlotinib or Gefitinib as First-Line Treatment for Patients with Stage IIIB/IV Non-Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ, Rochester, MN

  2. Study of the NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung

    Rochester, MN

  3. Dose Escalation and Double-blind Study of Veliparib in Combination With Carboplatin and Etoposide in Treatment-naive Extensive Stage Disease Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  4. BAY 1895344 Plus Topoisomerase-1 (Top1) Inhibitors in Patients with Advanced Solid Tumors, Phase I Studies with Expansion Cohorts in Small Cell Lung Carcinoma (SCLC), Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) and Pancreatic Adenocarcinoma (PDA)

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  5. Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination with Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer

    Rochester, MN

  6. Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

    Scottsdale/Phoenix, AZ

  7. A Study Comparing Sublobar Resection versus Stereotactic Ablative Radiotherapy for Lung Cancer

  8. A Study of Neoadjuvant/Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer (AEGEAN)

    Scottsdale/Phoenix, AZ

  9. Deuterated Phenanthrene Tetraol in Smokers Who Are at High Risk For Lung Cancer

    Rochester, MN

  10. A Study of Neoadjuvant Atezolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Patients With Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer (IMpower030)

    Rochester, MN

.

Mayo Clinic Footer